New Parkinson's Drug Approved in the US: One Pill a Day
Published
The U.S. Food and Drug Administration (FDA) approved a new drug for the treatment of Parkinson's disease at the end of September. The drug's brand name is JUVMO, and its generic name is tavapadon. The pharmaceutical company AbbVie developed the drug.
Parkinson's disease is a neurological disease that affects the nervous system and impacts movement. Patients may suffer from tremors, slowness of movement, and muscle stiffness. Patients generally require long-term, ongoing treatment, which is why new drugs are examined very carefully before they are approved.
According to the article, JUVMO is a pill taken once a day. The drug works differently from drugs that have existed until now, which is why some writers describe it as a "breakthrough." The article does not detail all of the study results, so the information on its efficacy and safety is still limited.
The FDA approval is an important step in the drug's development process. However, the article does not state when the drug will be available in Israel, and updates should be followed from the Ministry of Health and the authorized bodies in the country.
Sources: היום
More Israel news
- Israel and France Explore New Approaches to Mental Health Care
- Sudden Facial Paralysis and Diabetes: What a New Israeli Study Shows
- A U.S. Medical Delegation Visited Laniado Hospital in Netanya
- A Special Crossing Over Route 6: A Bridge for Wildlife
- Revolut Receives Conditional License to Establish a Bank in Israel
- Ministry of Health Cancels Water Boiling Order in Kfar Chabad
- Eisenkot and opposition leaders agree on candidates for key Knesset positions
- Exiled Iranian Prince: Iran Is Likely to Use Nuclear Weapons Against Israel